Paradox

$LUNR I'll do a deeper dive on this name later as part of the space economy list.

$RDW

$GME breakout on above average volume.

$BWXT – Nuclear Defense and Infrastructure Long-term investment idea (10+ years) as a nuclear power play with exposure to space exploration. The leading supplier of nuclear reactors, fuel, and components for the U.S. Navy and defense programs. Expanding into small modular reactors for future commercial and clean energy applications. Also partnering with NASA on nuclear propulsion technology for deep-space missions. Its BWXT Medical arm produces key radioisotopes used in roughly half of all PET scans in the U.S., providing steady, recurring cash flow. • Market Cap: $18.6B • Revenue: $2.86B +9.6% YoY • EPS: $2.89 • Free Cash Flow: $360M • Cash & Equivalents: $37M • Debt: $1.5B • Valuation: P/E 63.3x • Institutional Ownership: 97% • Dividend: 1.1% yield Risks: High valuation, heavy reliance on government contracts. Technical: Low-volume pullback to EMAs after reaching the 4.618 Fibonacci extension. Thoughts: Ideally, a pullback to $135–150 offers a better long-term entry. Strong trend with no major signs of slowing, overbought can stay overbought. I'll be patient on adding.

$BWXT – Nuclear Defense and Infrastructure Long-term investment idea (10+ years) as a nuclear power play with exposure to space exploration. The leading supplier of nuclear reactors, fuel, and components for the U.S. Navy and defense programs. Expanding into small modular reactors for future commercial and clean energy applications. Also partnering with NASA on nuclear propulsion technology for deep-space missions. Its BWXT Medical arm produces key radioisotopes used in roughly half of all PET scans in the U.S., providing steady, recurring cash flow. • Market Cap: $18.6B • Revenue: $2.86B +9.6% YoY • EPS: $2.89 • Free Cash Flow: $360M • Cash & Equivalents: $37M • Debt: $1.5B • Valuation: P/E 63.3x • Institutional Ownership: 97% • Dividend: 1.1% yield Risks: High valuation, heavy reliance on government contracts. Technical: Low-volume pullback to EMAs after reaching the 4.618 Fibonacci extension. Thoughts: Ideally, a pullback to $135–150 offers a better long-term entry. Strong trend with no major signs of slowing, overbought can stay overbought. I'll be patient on adding.

$ASTS I wonder if anyone is paying attention to these posts. So, do you see why I said pullback between now and then? 4.618 fib level, upper channel resistance. There was little room to go higher. Patience for now.

$ATAI Three questions: What are we looking at here? Will $CMPS follow? Why?

$CMPS has been holding up quite well. May see a little more downside to test the 50MA around $5 after testing a major resistance zone. Needs to reclaim the 200MA for possible 100% + move.

$ATAI has a beautiful rounding bottom pattern. It's right at $6 resistance. A breakout above targets $11.92 with a resistance wall between $17-23. If it can hold the trend, $36 longer term.

$MNMD has been in a consolidation phase for over a year. MindMed is a biotech company developing psychedelic treatments for mental disorders, including generalized anxiety, major depressive disorder, and autism. Two main drugs in their pipeline: • MM120 – Phase 3 trials for generalized anxiety & major depressive disorder • MM402 – Phase 1 trial for autism spectrum disorder BlackRock holds an 8% stake.

$CMPS shared in the trenches. Already up over 45%.

$LUNR I'll do a deeper dive on this name later as part of the space economy list.

$TGT Moving averages say "no touch" Pattern says "falling wedge"